ReviewDrugs & aging2013
Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management.
Review in Drugs & aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Non-pharmacological interventions for Lewy body dementia: a systematic review.Psychological medicine · 2018Pooled it
- The high cost of care and limited evidence on cost-effective strategies for Lewy body dementia: systematic review of evidence.BJPsych open · 2024Review
- Alzheimer's disease and Alzheimer's disease-related dementias in Hispanics: Identifying influential factors and supporting caregivers.Ageing research reviews · 2024Review
- A Confirmatory and an Exploratory Factor Analysis of the Cohen-Mansfield Agitation Inventory (CMAI) in a European Case Series of Patients with Dementia: Results from the RECage Study.Brain sciences · 2023Article
- Association of Variation in Behavioral Symptoms With Initial Cognitive Phenotype in Adults With Dementia Confirmed by Neuropathology.JAMA network open · 2022Article
- Case Study 3: A 58-Year-Old Woman Referred for Evaluation of Suspected Alzheimer Dementia.The Journal of neuropsychiatry and clinical neurosciences · 2022Article
- Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results.Alzheimer's research & therapy · 2021Article
- Delirium Assessment in Critically Ill Older Adults: Considerations During the COVID-19 Pandemic.Critical care clinics · 2021Review
- Multivariate genome wide association and network analysis of subcortical imaging phenotypes in Alzheimer's disease.BMC genomics · 2020Article
- New evidence on the management of Lewy body dementia.The Lancet. Neurology · 2020Review
- Clinical drug development for dementia with Lewy bodies: past and present.Expert opinion on investigational drugs · 2019Review
- Structural Brain Correlates of Attention Dysfunction in Lewy Body Dementias and Alzheimer's Disease.Frontiers in aging neuroscience · 2018Article
- Dementia With Lew Body: Impacts of Surgery.American journal of Alzheimer's disease and other dementias · 2016Review
- NephroCheck data compared to serum creatinine in various clinical settings.BMC nephrology · 2015Article
- Lewy body dementias.Lancet (London, England) · 2015Review
- Psychosis.Continuum (Minneapolis, Minn.) · 2015Review
- Clinical characterization of mild cognitive impairment as a prodrome to dementia with Lewy bodies.American journal of Alzheimer's disease and other dementias · 2015Article
- The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.Alzheimer's research & therapy · 2015Article
- Comprehensive treatment of dementia with Lewy bodies.Alzheimer's research & therapy · 2015Article
- Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia.Journal of neurology · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are synucleinopathies that lead to neurodegeneration and dementia. Although they result in symptoms common to Alzheimer's disease, they are associated with early emergence of parkinsonism and high frequency of neuropsychiatric symptoms, most commonly hallucinations and delusions. This review summarizes the current understanding of the underlying biology of neuropsychiatric symptoms in DLB and PDD and the evidence base for treatment to address them. Disruption to cholinergic and serotonergic neurotransmission and synapse activity are highlighted as primary pathological factors in neuropsychiatric symptoms, particularly loss of key neurotransmitter functions, alterations to neuronal receptors in the serotonergic pathway, and regionally specific structural changes that are linked to specific symptoms. Review of options for pharmacological treatment of neuropsychiatric symptoms suggests that the best evidence for the value of treatment is for cholinesterase inhibitors, with an indication that people with visual hallucinations are particularly likely to benefit. Evidence for the benefits of antipsychotics other than clozapine is limited, and there are serious safety concerns about the use of antipsychotics in these patients. Evidence to support other pharmacological interventions is very preliminary. Nonpharmacological approaches based on person-centered care and cholinesterase inhibitors should be considered as the first-line treatment for neuropsychiatric symptoms except in extreme cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.